CAR T Archives -

Events/ Events/ Oncology

BCMA Targeted Therapies Summit

Rhianna Price adc, BCMA, CAR T, multiple myeloma, Oncology 0 Comment

Revolutionize your BCMA pipeline

BCMA Targeted Therapies Summit

https://pharmaphorum.com/events/bcma-targeted-therapies-summit-2/

Events/ Events/ Oncology

Next Generation CAR-TCR Summit

Ellie Saunders cancer, CAR T, cell therapy, Oncology, T-cell 0 Comment

Engineering Smarter Adoptive Cell Therapies

Next Generation CAR-TCR Summit

https://pharmaphorum.com/events/next-generation-car-tcr-summit/

News/ News/ Oncology

FDA halts Allogene CAR-T trial after safety scare

Phil Taylor Allogene, CAR T, cell therapy, immuno-oncology, lymphoma, Oncology, safety 0 Comment

A phase 1 trial of Allogene’s of-the-shelf CAR-T for lymphoma has been placed on hold by the FDA,

FDA halts Allogene CAR-T trial after safety scare

https://pharmaphorum.com/news/fda-halts-allogene-car-t-trial-after-safety-scare/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

News/ News/ Oncology

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

Richard Staines Allogene, CAR T, Gilead, Kite Pharma, non-Hodgkin lymphoma, Oncology 0 Comment

In 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

https://pharmaphorum.com/news/allogene-announces-pivotal-trial/

R&D/ Views & Analysis/ Views and analysis

Collaboration is key to advancing cell therapy research

mike.hammerton@pharmaphorum.com CAR T, cell therapy, Gilead, Kite 0 Comment

Dr. Anne Kerber, VP, Head of Clinical Development, Europe at Kite, a Gilead Company, explains how the company

Collaboration is key to advancing cell therapy research

https://pharmaphorum.com/r-d/collaboration-is-key-to-advancing-cell-therapy-research/

News/ News/ Oncology

FDA approves BMS’ multiple myeloma CAR-T Abecma

Richard Staines Abecma, Bristol-Myers Squibb, CAR T, multiple myeloma 0 Comment

The FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat

FDA approves BMS’ multiple myeloma CAR-T Abecma

https://pharmaphorum.com/news/fda-approves-bms-multiple-myeloma-car-t-abecma/

Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis

Lymphoma Action – championing the patient voice in cell therapy

Susan Wormald CAR T, cell therapy, Gilead, Kite, lymphoma, Lymphoma Action, patients 0 Comment

Lymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill

Lymphoma Action – championing the patient voice in cell therapy

https://pharmaphorum.com/market-access-2/lymphoma-action-championing-the-patient-voice-in-cell-therapy/

Market Access/ News/ News

NHS and Kite sign access deal for Kite’s cancer cell therapy Tecartus

Richard Staines CAR T, Gilead, Kite, lymphoma, market access, NICE, Oncology, Tecartus 0 Comment

NHS patients in England will be among the first in the world to receive Gilead’s Tecartus cancer cell

NHS and Kite sign access deal for Kite’s cancer cell therapy Tecartus

https://pharmaphorum.com/news/nhs-kite-cancer-therapy/

Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis

Why cell therapy manufacture is a team sport

mike.hammerton@pharmaphorum.com cancer, CAR T, cell therapy, EU, Europe, Gilead, Kite, manufacturing 0 Comment

Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that

Why cell therapy manufacture is a team sport

https://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/

Trending

CAR T

Login